As I expected, FDA clearance for InVivage now is (hopefully) a 2025 approval. With all the other things going on with OIL as detailed in this presentation, very exciting, but from my, admittedly cheap seats, view, it is a slow 2024 coming from a revenue perspective. However, happy they have survived through tough times and continually doing amazing things on the tech side of things.
I am concerned on the push on the US office/sales team with the oral device so far in the future. But there is so much going on with the company now, I assume management have a way to keep costs managed well enough with sales with other tech.
How do others see this presentation?
Ann: OIL Managing Director's Presentation & Chair's Address, page-2
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.7M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 14.5¢ | 12.8¢ | $127.2K | 932.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 80000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
13.5¢ |
Change
0.000 ( 3.57 %) |
||||
| Open | High | Low | Volume | ||
| 13.0¢ | 14.5¢ | 12.5¢ | 712453 | ||
| Last updated 15.57pm 05/06/2024 ? | |||||
| OIL (ASX) Chart |